On September 4, 2019 Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, reported the following two new additions to its senior leadership team (Press release, Synlogic, SEP 4, 2019, View Source [SID1234539307]):
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Richard Riese, M.D., Ph.D., has been appointed to the position of Chief Medical Officer, and will assume responsibilities from current president and CEO, Aoife Brennan, M.B., Ch.B.
Michael Slater, a former consultant to the Company, has been appointed to Head of Regulatory Affairs.
Separately, the company is announcing the departure of Todd Shegog, Chief Financial Officer, effective September 18, 2019.
"Richard and Michael bring expertise and many years of experience across all phases of clinical development in a broad range of rare and immunologically-based diseases, which will be key to Synlogic’s success as we advance and expand our Synthetic Biotic therapeutic platform," said Dr. Brennan. "We are excited to welcome them both to the team and look forward to their contributions."
"Synlogic is a leader in developing engineered bacteria as living medicines and has demonstrated its ability to advance these novel therapeutics into clinical trials," stated Dr. Riese. "I believe that its Synthetic Biotic platform has the potential to provide a novel therapeutic solution to address unmet medical need in a variety of conditions and I look forward to advancing this exciting new therapy to patients."
Dr. Riese is a physician scientist with over 15 years of experience in the pharmaceutical industry. He most recently served as Vice President, Clinical Development at Alnylam where he led clinical development projects in several areas across Alnylam’s rare disease portfolio. Previously, he served as head of Translational Clinical Sciences in the Research Unit at Alexion, where he was responsible for the clinical development strategy of all compounds from discovery to proof-of-concept. He earned a Ph.D. in biophysics and an M.D. from the Medical College of Wisconsin, and a B.S. in mathematics from the University of Wisconsin-Madison. Dr. Riese carried out postdoctoral research at the Medical College of Wisconsin and his residency training in internal medicine at Brigham and Women’s Hospital in Boston. Dr. Riese achieved certification by the American Boards of Pulmonary Medicine, Critical Care Medicine and Internal Medicine.
Mr. Slater is a senior level regulatory professional with more than 25 years of experience including hands-on preclinical and clinical regulatory strategy development from pre-investigational new drug (IND) application through drug approval. Mr. Slater was the Head of Regulatory Affairs and later, Development Operations at Merrimack Pharmaceuticals from 2010 to 2019. At Merrimack, Mr. Slater led the regulatory strategy resulting in the 2015 U.S. approval of Onivyde (irinotecan liposome injection), an orphan drug for the treatment of metastatic pancreatic cancer. In addition, he worked with Baxalta who acquired certain ex-US rights to Onyvide, to achieve approval in Europe and other countries. Prior to Merrimack, Mr. Slater held various regulatory roles in several biotech and pharmaceutical companies, including Millennium Pharmaceuticals, Acusphere, Inc., Anika Therapeutics, Inc., ImmuLogic Pharmaceuticals, Biogen and Hoechst Pharmaceuticals. With a background in applied biology, Mr. Slater also holds a B.Sc. in information science from Leeds Beckett University, UK. and is a Fellow of The Organization for Professionals in Regulatory Affairs.
In addition, the Company is announcing the departure of Todd Shegog, Chief Financial Officer, who is leaving the company to pursue another opportunity. The Company has commenced a search for a new CFO.
"I also want to take the opportunity to thank Todd for his contributions at Synlogic over the past three years, including leading us through the process of becoming a public company, and establishing a strong financial team and our internal controls and financial operations," said Dr. Brennan. "We have appreciated his leadership and wish him all the best in his future endeavors."